MHRA Authorized Bayer’s Lynkuet For Wider VMS Use
▫️The UK Medicines And Healthcare Products Regulatory Agency (MHRA) Has Authorized An Extension to The Indication For Bayer’s Lynkuet (Elinzanetant) For The Treatment of Moderate to Severe Vasomotor Symptoms (VMS), Also Known As Hot Flushes, Caused by Adjuvant Endocrine Therapy (AET) Related to Breast Cancer.
▫️Elinzanetant, A Dual Neurokinin-Targeted, Hormone-Free Therapy, Antagonizing NK-1 And NK-3 Receptors, Is The First And Only Treatment Option Approved in The UK For This Indication, The German Pharma Major Noted.
@MedicalNoteBook
2
1August 17, 2026 119 1
